Achieve Life Sciences Inc. presented updates on cytisinicline, a potential new treatment for nicotine dependence and smoking cessation. The company highlighted that cytisinicline is positioned to address an estimated market of up to 50 million Americans who use tobacco. The presentation noted that cytisinicline has been awarded Breakthrough Therapy designation by the FDA for vaping cessation and has received a Commissioner's National Priority Voucher. The drug features a highly selective mechanism of action and demonstrated efficacy and tolerability in both 6- and 12-week treatment durations, including among treatment-resistant smokers. The company outlined a targeted launch strategy and anticipated Affordable Care Act coverage for the product. Expected milestones include FDA review and potential approval for smoking cessation in 2026, with additional opportunities in vaping cessation and relapse prevention. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.